key: cord-0750731-48f9ii54 authors: Goodnough, Lawrence T title: Blood management: transfusion medicine comes of age date: 2013-05-24 journal: Lancet DOI: 10.1016/s0140-6736(13)60673-x sha: c2a811dab8fa854dc71dfae8de6beee6f0ad91cc doc_id: 750731 cord_uid: 48f9ii54 nan Blood transfusions happen in more than 10% of all hospital stays that include a procedure. The American Medical Association 1 identifi ed overuse of fi ve medical treatments-blood transfusions, along with cardiac stents, ear tubes, antibiotics, and the induction of birth in pregnant women-and highlighted the danger of unnecessary transfusions. Although blood transfusions are believed to be lifesaving, this assumption has never been shown in a controlled clinical trial; blood transfusions have been described as "unavoidably, unsafe, and inherently dangerous" in the US Blood Shield laws. 2 Thus, perceived benefi ts relative to the known risks of a blood transfusion are important elements in discussions with patients about informed consent, especially in management of anaemia with alternatives to blood transfusion. 3 Transfusion-transmitted infections have been a worry, especially in the 1980s with the recognition of transfusion-associated HIV and the risk of trans mission of hepa titis C virus. 4 Transmission of known viral agents has decreased and responses to emerging infectious diseases trans mitted by blood transfusion have been rapid (fi gure). Concomitantly, the 2011-12 annual report of transfusion fatalities by the US Food and Drug Administration Center for Biologics Evaluation and Research showed a decrease in all-cause deaths related to transfusion, with only 30 deaths attributable to transfusion reported in the USA in 2011. 5 Between 20x07 and 2011, transfusion-related acute lung injury caused the highest percentage (43%) of reported fatalities, followed by haemolytic transfusion reactions (23%) caused by non-ABO (13%) or ABO (10%) incompatibilities. Increasing evidence suggests that patients have additional adverse clinical outcomes (ie, increased mor bid ity and mortality) associated with blood transfusions. 6 The panel lists risks that include not only known transmissible pathogens for infectious disease, transfusion reactions, transfusion-related acute lung injury, errors in blood administration, and circulatory overload; but also potential, as yet undefi ned, risks such as immunomodulation (eg, perioperative infection or tumour progression), unknown risks (emerging pathogens such as new variant Creutzfeldt-Jakob disease and West Nile virus), 4 and risks associated with duration of blood storage lesions in patients undergoing cardiac surgery. 7 The potential threat of xenotropic murine leukemia virus-related virus (XMRV), for example, required exten sive research to determine that its presence in the blood of patients with chronic fatigue syndrome could not be reproducibly confi rmed, and that blood donor screening is not warranted. 8 These considerations have given rise to the specialty of blood management, supported by corresponding initiatives to "promote the app ropriate use of blood and blood components, with a goal of minimizing their use". This movement has been motivated by the need to improve blood safety and patient outcomes, preserve the blood inventory, and constrain escalating costs. 9 Patient blood management has been recognised by WHO as a means to "promote the availability of transfusion alternatives". 10 In 2010, blood management was cited as one of the ten key advances in transfusion medicine in the past 50 years. 11 Awareness of risks, costs, and the eff ect on blood inventory has led providers to look at institution-based initiatives in patient blood management, such as the use of guidelines restricting use of transfusion to improve blood use. 12 Patient blood management encompasses an evidence-based medical and surgical approach that is multidisciplinary (ie, including transfusion medi cine specialists, surgeons, anaesthesiologists, and critical care specialists) and multiprofessional (ie, including physicians, nurses, pump technologists, and pharmacists). In this approach, preventive strategies are emphasised to identify, assess, and manage anaemia in medical 13 and surgical 14 patients, including use of pharmacological interventions 15 and the avoidance of unnecessary diagnostic teting to minimise iatrogenic blood loss; 16 to optimise homoeostasis 17 and use of point-of-care testing; 18 and to establish clinical practice guidelines for blood transfusions. With recent development of qualityperformance indicators for patient blood management by health-care institutions and accreditation organisations, 3 the accompanying Clinical Series in The Lancet is appropriate and timely, and looks at the eff ect of patient blood management on three areas of transfusion medicine: blood utilisation, alternatives to blood, and inventory management of the blood supply. Departments of Pathology and Medicine, Stanford University, Stanford, CA 94305, USA ltgoodno@stanford.edu I declare that I have no confl icts of interest. Legal liability for transfusion injury in the acquired immunodefi ciency syndrome era Patient blood management Transfusion-associated infections: 50 years of relentless challenges and remarkable progress Fatalities reported to FDA following blood collection and transfusion. Annual summary for fi scal year 2011 Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation Transfusion of older stored blood and risk of death: a meta-analysis Failure to confi rm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study Of mad cows and bolted horses: the economics of blood safety World Health Organization. 63rd World Health Assembly. Availability, safety and quality of blood products Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION Approaching Illness as a Team Detection, evaluation, and management of iron-restricted erythropoiesis Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines Special article: current status of pharmacologic therapies in patient blood management Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes The Joplin Globe. Decline in need for blood leads to staff cuts at center. Medical errors (wrong blood to patient because of mislabelled specimen or patient misidentifi cation) 5 Transfusion-associated acute lung injury 6 Transfusion-associated circulatory overload 7 Iron overload 8 Immunomodulation 9 Storage lesions (age of blood) *The target of the screening assay (antibody, microbial antigen, or microbial nucleic acid) and the year of assay implementation are shown in parentheses. Updated from reference 3.